NASDAQ$ADAPY
Adaptimmune Therapeutics Plc · Q3 2024 earnings
Q3 2024 earnings · · After market close · Investor relations
Briefing
Adaptimmune reported financial results and business updates.
Adaptimmune reported Q3 2024 financial results, highlighted by revenue of $40.9 million and total liquidity of $186.1 million. The company is restructuring to focus on its sarcoma franchise and high-potential R&D programs, targeting operating breakeven in 2027.
- Tecelra launch is on track with 9 Authorized Treatment Centers available.
- First patient apheresed in Q3, with commercial revenues expected in Q4 and acceleration throughout 2025.
- Lete-cel IGNYTE-ESO pivotal trial reported a 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS).
- Company restructuring includes a planned 33% headcount reduction in Q1 2025, aiming for approximately $300 million in cost savings over the next four years.
Headline financials
Revenue & EPS history
Adaptimmune · Revenue · Quarterly
$40.9M
Revenue by segment
Adaptimmune · $1.42M total across 1 segment · Q4 2021
- Development revenue$1.42M—100.0%
Forward guidance
Adaptimmune is focused on prioritizing its commercial sarcoma franchise and R&D programs with the highest potential, aiming for operating breakeven in 2027 through significant cost reductions.
Tailwinds
- Tecelra launch progressing with 9 active Authorized Treatment Centers.
- First commercial revenues from Tecelra expected in Q4 2024, with growth anticipated in 2025.
- Lete-cel pivotal trial showed a 42% overall response rate in specific sarcoma subtypes.
- Plans to initiate a rolling BLA submission for lete-cel by the end of 2025.
- Company projects $400 million peak year sales for the combined sarcoma franchise.
Headwinds
- Planned 33% reduction in headcount in Q1 2025 as part of restructuring.
- Ceasing enrollment in the SURPASS-3 Phase 2 clinical trial for uza-cel in ovarian cancer.
- Operating expenses expected to be reduced by approximately 25% in the first year.
- Aggregate savings of approximately $300 million over four years exclude one-time restructuring costs.
- Net loss of $17.6 million for the quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
-3.0%
Avg return
Earnings day
-7.9%
Avg return
5 days after
-3.2%
Avg return
30 days after
37%
16 / 43 earnings
Positive
+26.5%
Q3 2022
Best reaction
-37.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +0.0% | -90.0% | — | |
| Q3 2025 | +0.0% | -90.0% | — | |
| Q2 2025 | +1.3% | -9.1% | -27.3% | |
| Q1 2025 | +4.7% | +0.7% | -7.9% | |
| Q4 2024 | -37.7% | -44.3% | -47.0% | |
| Q3 2024 | -25.5% | +12.5% | -1.9% | |
| Q2 2024 | +5.8% | +8.8% | +8.8% | |
| Q1 2024 | +4.3% | -4.3% | -12.2% | |
| Q4 2023 | +19.2% | +5.5% | -6.2% | |
| Q3 2023 | -8.2% | -20.6% | -8.6% | |
| Q2 2023 | -5.2% | -8.7% | -14.5% | |
| Q1 2023 | +2.2% | -1.5% | -27.4% | |
| Q4 2022 | -29.0% | -36.4% | -40.3% | |
| Q3 2022 | +26.5% | +51.2% | +6.0% | |
| Q2 2022 | +20.6% | +14.4% | +4.1% | |
| Q1 2022 | -8.8% | -17.5% | -0.6% | |
| Q4 2021 | -4.9% | +19.8% | +7.7% | |
| Q3 2021 | +0.0% | +0.7% | -34.6% | |
| Q2 2021 | +2.3% | +14.3% | +79.1% | |
| Q1 2021 | -6.6% | -6.7% | -7.4% | |
| Q4 2020 | -7.5% | -9.3% | -14.4% | |
| Q3 2020 | -1.7% | -7.9% | -15.7% | |
| Q2 2020 | -8.5% | -6.8% | -8.9% | |
| Q1 2020 | +2.4% | +13.9% | +118.9% | |
| Q4 2019 | +3.1% | -0.3% | -18.8% | |
| Q3 2019 | -18.2% | -25.6% | +1.8% | |
| Q2 2019 | -23.7% | -36.0% | -51.1% | |
| Q1 2019 | -6.9% | -9.1% | -18.1% | |
| Q4 2018 | -9.7% | -12.1% | -11.5% | |
| Q3 2018 | -6.7% | -13.3% | -19.4% | |
| Q2 2018 | -8.7% | -8.3% | +19.0% | |
| Q1 2018 | +2.6% | -0.5% | -1.2% | |
| Q4 2017 | +20.1% | +12.5% | +35.2% | |
| Q3 2017 | +8.8% | +8.8% | +7.9% | |
| Q2 2017 | +1.7% | +2.4% | +23.2% | |
| Q1 2017 | -3.0% | +4.1% | +0.6% | |
| Q3 2016 | +2.9% | +0.0% | -14.6% | |
| Q2 2016 | -7.2% | -12.6% | -16.9% | |
| Q1 2016 | -5.1% | — | — | |
| Q3 2015 | -10.5% | — | — | |
| Q4 2015 | -10.5% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q2 2015 | -0.8% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro